CTLA4 and renal carcinoma: In addition, by analyzing gene expression profiles from renal cancer-bearing mice treated with an anti-PD-L1 and anti-CTLA-4 combination therapy, we confirmed that renal cancer-bearing mice responding to immunotherapy had a lower level of ARHGAP11A (Figure 7F).